Biolase Inc (BIOL) Stock: The Story of a 52-Week Stock Range

Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Biolase Inc’s current trading price is -99.14% away from its 52-week high, while its distance from the 52-week low is 26.80%. The stock’s price range during this period has varied between $0.35 and $52.00. The company, active in the Healthcare sector, saw a trading volume of around 0.86 million for the day, considerably higher average daily volume of 4.17 observed over the last three months.

Biolase Inc had a pretty Dodgy run when it comes to the market performance. Over the past year, the company’s stock reached a high of $52.00 on 03/01/23, while the lowest price during the same period was $0.35 on 02/07/24.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

How Financial Performance Impacts Market Capitalization

Biolase Inc (BIOL) has experienced a quarterly decline of -68.60% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.54M and boasts a workforce of Jun 24 2005 employees.

The Role of Moving Averages and Trading Volume in Technical Analysis

Based on Barchart.com data, the company’s moving average over the 100-day period was 1.2882, with a change in price of -1.6410. Similarly, Biolase Inc recorded 272,686 in trading volume during the last 100 days, posting a change of -78.52%.

How BIOL’s Debt-to-Equity Ratio Affects Financial Health

A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for BIOL stands at 65.24. Similarly, the long-term debt-to-equity ratio is also 54.09.

BIOL Stock Stochastic Average

As of today, the raw stochastic average of Biolase Inc over the last 50 days is at 6.22%. This shows a declinee from the raw stochastic average of the previous 20 days, which was recorded at 13.44%. Further, the company’s Stochastic %K and %D values for the last 20 days were 14.32% and 9.62%, respectively.

BIOL Stock Price Performance Analysis

Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. This year’s metric has recorded a Price decrease of -59.98%. However, over the past six months, we’ve seen a stronger performance of -91.50%. The price of BIOL leaped by -56.41% over the last 30 days. And in the last five days, it has fallen by -35.86%.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts